Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; September 19, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug ALTO-100, which failed to meet primary endpoints in clinical trials, leading to significant stock price decline [3][4][5]. Group 1: Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company focused on developing treatments for major depressive disorder (MDD) [3]. - The company conducted its initial public offering (IPO) on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Group 2: Allegations and Impact - The lawsuit claims that during the Class Period, Alto Neuroscience made false or misleading statements about the effectiveness of ALTO-100, overstating its clinical and commercial prospects [4]. - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - As of the filing of the class action, Alto Neuroscience's stock continues to trade below the IPO price of $16.00 per share [6].